Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules

COLUMBUS, Ohio, June 18 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Ramipril Capsules, 1.25mg, 2.5mg, 5mg and 10mg by the U.S. Food and Drug Administration. The 1.25mg, 2.5mg, 5mg and 10mg strengths will be available in various packaging configurations. Roxane Laboratories Ramipril Capsules are available for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: )

Roxane Laboratories' Ramipril Capsules are AB rated to ALTACE(R) (ramipril) Capsules. Annual sales of Ramipril Capsules, 1.25mg, 2.5mg, 5mg and 10mg are approximately $932 Million(1).

Roxane Laboratories' Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Please refer to the full prescribing information for a list of the most commonly reported side effects.

Full prescribing information for Ramipril Capsules is available on the Roxane Laboratories website at or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit

(1) IMS MAT dollar sales ending 03/2008

ALTACE(R) is a registered trademark of King Pharmaceuticals, Inc.

SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
2. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
3. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
4. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
5. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
6. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
7. Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development
8. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings
10. Stiefel Laboratories, Inc. Appoints New President
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... On November 25, 2015, officials of Narconon Arrowhead ... the release of a new cutting edge recovery program that has been 50 years ... drug- and alcohol-addicted individuals with the purpose to free addicts from the symptoms and ...
(Date:11/25/2015)... ... ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David Adcock ... , According to court documents, Adcock testified that on May 10, 2010 he sat ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... , ... November 25, 2015 , ... In an ongoing ... Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its ... surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 at ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology: